Effect of 2 years of high-dose growth hormone therapy on cognitive and psychosocial development in short children born small for gestational age

Lagrou, K.; Vanderfaeillie, Johan; Froidecoeur, Christelle; Thomas, Muriel; Massa, Guy; Tenoutasse, Sylvie; Craen, Margarita; Lebrethon, Marie-Christine; Beckers, Dominique; François, Inge; Rooman, Raoul; Thiry-Counson, G.; Beaufort, Carine de; Schepper, Jean De

doi:10.1530/eje.1.02335

Cited by 20 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in contrast with the findings in a cohort of SGA children from Belgium. In a randomized controlled trial, no beneficial effect of GH treatment on IQ scores could be observed after 2 years of treatment [6]. A remarkable finding in this study was an increase in IQ scores of about 8 points in untreated SGA children.…”

Section: Gh Therapy and Brain Development Intelligence And Cognitionmentioning

confidence: 58%

“…There are 2 cohorts of SGA children in which the effect of GH therapy on intelligence and cognition has been evaluated [5,6,83,84]. …”

Section: Gh Therapy and Brain Development Intelligence And Cognitionmentioning

confidence: 99%

“…The effect of GH therapy on height has been carefully documented [1]. Interestingly, one group described an effect of GH on intelligence and cognition in SGA children [5], whereas another group did not find any significant effect of GH on intelligence [6]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Brain Development, Intelligence and Cognitive Outcome in Children Born Small for Gestational Age

2010

View full text Add to dashboard Cite

Intrauterine growth restriction (IUGR) can lead to infants being born small for gestational age (SGA). SGA is associated with increased neonatal morbidity and mortality as well as short stature, cardiovascular disease, insulin resistance, diabetes mellitus type 2, dyslipidemia and end-stage renal disease in adulthood. In addition, SGA children have decreased levels of intelligence and cognition, although the effects are mostly subtle. The overall outcome of each child is the result of a complex interaction between intrauterine and extrauterine factors. Animal and human studies show structural alterations in the brains of individuals with IUGR/SGA. The presence of growth hormone (GH) receptors in the brain implies that the brain is also a target for GH. Exogenous GH theoretically has the ability to act on the brain. This is exemplified by the effects of GH on cognition in GH-deficient adults. In SGA children, data on the effect of exogenous GH on intelligence and cognition are scant and contradictory.

show abstract

Section: Gh Therapy and Brain Development Intelligence And Cognitionmentioning

confidence: 58%

“…There are 2 cohorts of SGA children in which the effect of GH therapy on intelligence and cognition has been evaluated [5,6,83,84]. …”

Section: Gh Therapy and Brain Development Intelligence And Cognitionmentioning

confidence: 99%

See 1 more Smart Citation

Brain Development, Intelligence and Cognitive Outcome in Children Born Small for Gestational Age

2010

View full text Add to dashboard Cite

show abstract

“…SHTAC excluded the review by Lagrou (2007) as its outcomes did not meet our inclusion criteria. We also excluded the reviews by Bundak (2001) …”

Section: Searches Identified (Studies For Genotropin)mentioning

confidence: 99%

Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation

Takeda

Cooper²,

Bird³

et al. 2010

Health Technol Assess

110

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. F...

show abstract

“…In young children born SGA, normalized head circumference was found in the 3-year GH-treated group but not in the untreated group [5], with concomitant positive effects on intelligence and psychosocial functioning [1]. In contrast, IQ in non-GH-deficient SGA children did not improve with GH treatment [6], whereas IQ did improve in children with Prader-Willi syndrome with severe GHD [2]. …”

Section: Introductionmentioning

confidence: 99%

Growth Hormone Treatment Improves Cognitive Function in Short Children with Growth Hormone Deficiency

Chaplin

Kriström²,

Jonsson³

et al. 2015

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aims: We investigated the association between cognition and growth hormone (GH) status and GH treatment in short prepubertal children with broadly ranging GH secretion. Methods: A total of 99 children (age 3-11 years), 41 with GH deficiency (GHD) and 58 with idiopathic short stature (ISS), were randomized to a fixed dose (43 µg/kg/day) or a prediction model-guided individualized dose (17-100 µg/kg/day) and followed up for 24 months. In a longitudinal and mixed within- and between-subjects study, we examined clinical effect size changes, measured by Cohen's d, in full-scale IQ (FSIQ) and secondary IQ indices. Results: Significant increases giving medium effect size in FSIQ (p = 0.001, Cohen's d = 0.63), performance IQ (p = 0.001, Cohen's d = 0.65) and processing speed (p = 0.005, Cohen's d = 0.71) were found in the GH-deficient group. In contrast, perceptual organization only increased in the ISS group (p = 0.001, Cohen's d = 0.53). Baseline IQ was normally distributed with small but significant differences between the groups: GH-deficient children had lower FSIQ (p = 0.042) and lower performance IQ (p = 0.021). Using multiple regression analysis, 40% of the variance in delta processing speed scores (0-24 months) was explained by GH_max and IGF-I_SDS at baseline. Conclusion: IQ, specifically fluid intelligence, increased in the GH-deficient children. The pretreatment status of the GH/IGF-I axis was significantly predictive for these changes.

show abstract

Effect of 2 years of high-dose growth hormone therapy on cognitive and psychosocial development in short children born small for gestational age

Cited by 20 publications

References 29 publications

Brain Development, Intelligence and Cognitive Outcome in Children Born Small for Gestational Age

Brain Development, Intelligence and Cognitive Outcome in Children Born Small for Gestational Age

Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation

Growth Hormone Treatment Improves Cognitive Function in Short Children with Growth Hormone Deficiency

Contact Info

Product

Resources

About